HDSbio

HDSbio is a biotechnology company specializing in the development of long-acting injectable therapeutics for metabolic disorders, including obesity and type 2 diabetes. The company leverages its proprietary High-Density Surface (HDS) platform technology to create sustained-release formulations of peptides and small molecules, aiming to reduce dosing frequency to once-monthly or less. Its lead candidate, HDS-101, is a long-acting GLP-1 receptor agonist currently in the pre-clinical stage with plans for clinical entry. HDSbio's pipeline also includes multi-agonist programs targeting GLP-1, GIP, and Glucagon receptors to provide superior weight loss and metabolic benefits. The company was founded by industry veterans with significant experience in peptide drug development and is backed by prominent venture capital firms.